Advisor Group Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 10.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,855 shares of the company’s stock after purchasing an additional 1,721 shares during the period. Advisor Group Inc.’s holdings in Zoetis were worth $1,176,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Wells Fargo & Company MN lifted its stake in shares of Zoetis by 8.2% in the 2nd quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after purchasing an additional 389,260 shares during the last quarter. Swiss National Bank lifted its stake in shares of Zoetis by 8.1% in the 2nd quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after purchasing an additional 133,900 shares during the last quarter. Gladstone Capital Management LLP acquired a new position in shares of Zoetis in the 2nd quarter valued at $3,134,000. BlackRock Inc. lifted its stake in shares of Zoetis by 3.9% in the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after purchasing an additional 1,412,829 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Zoetis by 13.9% in the 2nd quarter. Victory Capital Management Inc. now owns 277,641 shares of the company’s stock valued at $17,320,000 after purchasing an additional 33,894 shares during the last quarter. 93.20% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Tuesday. BidaskClub lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, September 1st. Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Cowen and Company set a $70.00 price target on Zoetis and gave the company a “buy” rating in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company’s stock. Zoetis currently has an average rating of “Buy” and an average target price of $65.76.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/zoetis-inc-zts-stake-boosted-by-advisor-group-inc/1598546.html.

Shares of Zoetis Inc. (ZTS) opened at 63.76 on Friday. The stock has a market cap of $31.19 billion, a P/E ratio of 36.04 and a beta of 1.02. The firm’s 50-day moving average price is $62.44 and its 200 day moving average price is $59.64. Zoetis Inc. has a one year low of $46.86 and a one year high of $65.83.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the firm earned $0.49 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.